Found: 124
Select item for more details and to access through your institution.
Patient-reported burden in adults with atopic dermatitis: an international qualitative study.
- Published in:
- Archives of Dermatological Research, 2024, v. 316, n. 7, p. 1, doi. 10.1007/s00403-024-03130-w
- By:
- Publication type:
- Article
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
- Published in:
- Archives of Dermatological Research, 2024, v. 316, n. 7, p. 1, doi. 10.1007/s00403-024-03122-w
- By:
- Publication type:
- Article
Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 10, p. 1066, doi. 10.1001/jamadermatol.2024.2701
- By:
- Publication type:
- Article
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).
- Published in:
- JAMA Dermatology, 2023, v. 159, n. 2, p. 182, doi. 10.1001/jamadermatol.2022.5534
- By:
- Publication type:
- Article
Follow-up of Patients With Keratinocyte Carcinoma: A Systematic Review of Clinical Practice Guidelines.
- Published in:
- 2023
- By:
- Publication type:
- journal article
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 3, p. 485, doi. 10.1007/s40257-024-00853-4
- By:
- Publication type:
- Article
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 2, p. 299, doi. 10.1007/s40257-024-00846-3
- By:
- Publication type:
- Article
Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 1, p. 127, doi. 10.1007/s40257-023-00810-7
- By:
- Publication type:
- Article
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 6, p. 939, doi. 10.1007/s40257-023-00806-3
- By:
- Publication type:
- Article
Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 4, p. 595, doi. 10.1007/s40257-023-00792-6
- By:
- Publication type:
- Article
Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 2, p. 305, doi. 10.1007/s40257-022-00739-3
- By:
- Publication type:
- Article
Diagnosis of Generalized Pustular Psoriasis.
- Published in:
- American Journal of Clinical Dermatology, 2022, v. 23, n. 1, p. 31, doi. 10.1007/s40257-021-00652-1
- By:
- Publication type:
- Article
Phosphodiesterase-4 Inhibition in the Management of Psoriasis.
- Published in:
- Pharmaceutics, 2024, v. 16, n. 1, p. 23, doi. 10.3390/pharmaceutics16010023
- By:
- Publication type:
- Article
Targeting Interleukin 13 for the Treatment of Atopic Dermatitis.
- Published in:
- Pharmaceutics, 2023, v. 15, n. 2, p. 568, doi. 10.3390/pharmaceutics15020568
- By:
- Publication type:
- Article
Acrodermatitis continua of Hallopeau successfully treated with adalimumab: A case report.
- Published in:
- SAGE Open Medical Case Reports, 2019, v. 7, p. N.PAG, doi. 10.1177/2050313X19829620
- By:
- Publication type:
- Article
Acrodermatitis continua of Hallopeau successfully treated with adalimumab: A case report.
- Published in:
- SAGE Open Medical Case Reports, 2019, v. 7, p. N.PAG, doi. 10.1177/2050313X19829620
- By:
- Publication type:
- Article
Hidradenitis suppurativa with SAPHO syndrome maintained effectively with adalimumab, methotrexate, and intralesional corticosteroid injections.
- Published in:
- SAGE Open Medical Case Reports, 2018, v. 6, p. 1, doi. 10.1177/2050313X18778723
- By:
- Publication type:
- Article
Development and validation of a new method for potential use of Psoriasis Area and Severity Index in teledermatology.
- Published in:
- Australasian Journal of Dermatology, 2021, v. 62, n. 1, p. e114, doi. 10.1111/ajd.13412
- By:
- Publication type:
- Article
Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
- Published in:
- BMC Dermatology, 2016, v. 16, p. 1, doi. 10.1186/s12895-016-0051-4
- By:
- Publication type:
- Article
Sex Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry.
- Published in:
- Journal of Psoriasis & Psoriatic Arthritis, 2022, v. 7, n. 3, p. 132, doi. 10.1177/24755303221099848
- By:
- Publication type:
- Article
Practice Patterns of Palmoplantar Pustulosis: Patient Demographics and Treatment Options.
- Published in:
- Journal of Psoriasis & Psoriatic Arthritis, 2022, v. 7, n. 3, p. 117, doi. 10.1177/24755303221099292
- By:
- Publication type:
- Article
Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc analysis of the JADE clinical trials.
- Published in:
- JEADV Clinical Practice, 2023, v. 2, n. 4, p. 753, doi. 10.1002/jvc2.203
- By:
- Publication type:
- Article
Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q).
- Published in:
- JEADV Clinical Practice, 2023, v. 2, n. 2, p. 282, doi. 10.1002/jvc2.126
- By:
- Publication type:
- Article
A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 10, p. 2877, doi. 10.1007/s13555-024-01268-z
- By:
- Publication type:
- Article
Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK Inhibitors.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 9, p. 2653, doi. 10.1007/s13555-024-01243-8
- By:
- Publication type:
- Article
More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 9, p. 2621, doi. 10.1007/s13555-024-01242-9
- By:
- Publication type:
- Article
Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2285, doi. 10.1007/s13555-024-01200-5
- By:
- Publication type:
- Article
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 5, p. 1145, doi. 10.1007/s13555-024-01158-4
- By:
- Publication type:
- Article
Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 5, p. 1211, doi. 10.1007/s13555-024-01155-7
- By:
- Publication type:
- Article
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 4, p. 1007, doi. 10.1007/s13555-024-01147-7
- By:
- Publication type:
- Article
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor).
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 2, p. 441, doi. 10.1007/s13555-023-01075-y
- By:
- Publication type:
- Article
Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 9, p. 1893, doi. 10.1007/s13555-023-00948-6
- By:
- Publication type:
- Article
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 4, p. 867, doi. 10.1007/s13555-023-00905-3
- By:
- Publication type:
- Article
Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 2, p. 535, doi. 10.1007/s13555-022-00870-3
- By:
- Publication type:
- Article
Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 1, p. 235, doi. 10.1007/s13555-022-00853-4
- By:
- Publication type:
- Article
Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 1, p. 269, doi. 10.1007/s13555-022-00849-0
- By:
- Publication type:
- Article
Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 11, p. 2499, doi. 10.1007/s13555-022-00805-y
- By:
- Publication type:
- Article
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 9, p. 2077, doi. 10.1007/s13555-022-00764-4
- By:
- Publication type:
- Article
Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 6, p. 1431, doi. 10.1007/s13555-022-00743-9
- By:
- Publication type:
- Article
Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 5, p. 1073, doi. 10.1007/s13555-022-00722-0
- By:
- Publication type:
- Article
Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 3, p. 727, doi. 10.1007/s13555-022-00690-5
- By:
- Publication type:
- Article
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 2, p. 495, doi. 10.1007/s13555-021-00649-y
- By:
- Publication type:
- Article